BANZEL® (rufinamide)
BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults
rufinamide
BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by whitelisting our website.